Advanced malignant tumors including, but not limited to, breast cancer, colorectal cancer, liver cancer, gastric cancer, non-small cell lung cancer, etc.
Conditions
Interventions
Group A:25 mg/m2 of Depoxythilone
Group B:50 mg/m2 of Depoxythilone
Group C:85 mg/m2 of Depoxythilone
Group D:125 mg/m2 of Depoxythilone
Group E:170 mg/m2 of Depoxythilone
Group F:225 mg/m2 of Depoxythilone
Sponsors
Cancer Hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
Male
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Histological or cytological confirmed diagnosis of advanced, recurrent or metastatic malignant tumors; 2. Patient with solid tumors that lack standard therapy or have progressed after standard therapy including patients who have previously treated with Taxol; 3. Age limits: min 18 years old, max: 65 years old, both male and female; 4. ECOG performance status of 0-1; Life expectancy of 3 months or more; 5. Adequate organ function for heart, liver, kidney and bone narrow; 6. At least 30 days since prior chemotherapy; 7. Fertile patients must use effective contraception; 8. Patients with measurable or evaluable target lesions; 9. Patient with good compliance, able to understand and willing to sign the written informed consent form.
Exclusion criteria
Exclusion criteria: 1. Severe and /or uncontrolled medical conditions, including severe cardiovascular disease, uncontrolled diabetes and high blood pressure, active infection, liver and kidney disorders; 2. Patients in pregnant or nursing; 3. Received any other investigational agents or non-approved drugs within 4 weeks preceding the first dose of UTD1; 4. Patient with uncontrollable mental disease and active infection; 5. Documented hypersensitivity reaction to Cremophor EL; 6. Patient unable to receive hormonotherapy, such as diabetes; 7. Patient with history of uncontrolled mental disease; 8. Patient with lower compliance; 9. Patient not fitted for this study determined by the principal investigator (PI).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical effect index;Safety;Clinical effect index; | — |
Countries
China
Contacts
Public ContactBinghe Xu
Outcome results
None listed